Boland, P. M., Lenz, H., Ciombor, K. K., Florou, V., Pishvaian, M. J., Cusnir, M., . . . Hochster, H. S. (2025). A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer. Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies, 43(1), 60-68. https://doi.org/10.1007/s10637-024-01489-1
Chicago-referens (17:e uppl.)Boland, Patrick M., et al. "A Phase 1b Study of the OxPhos Inhibitor ME-344 with Bevacizumab in Refractory Metastatic Colorectal Cancer." Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies 43, no. 1 (2025): 60-68. https://doi.org/10.1007/s10637-024-01489-1.
MLA-referens (9:e uppl.)Boland, Patrick M., et al. "A Phase 1b Study of the OxPhos Inhibitor ME-344 with Bevacizumab in Refractory Metastatic Colorectal Cancer." Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies, vol. 43, no. 1, 2025, pp. 60-68, https://doi.org/10.1007/s10637-024-01489-1.
